Literature DB >> 22374325

The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation.

Chiara Gasparini1, Alberto Tommasini, Giorgio Zauli.   

Abstract

Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, has been recently taken into consideration as a promising therapeutic tool for tumor treatment based on its ability to stabilize and activate the p53 transcription factor pathway. Since Nutlin-3 displays non cell-autonomous tumor-suppressor activities, we wanted to investigate its effect on dendritic cell functions, given the central role of these cells in the modulation of the immune response. We found that Nutlin-3 alone slightly affected the levels of major histocompatibility complex and costimulatory molecules and significantly promoted the ability of dendritic cells to stimulate T cells in the mixed lymphocyte reaction. Taken together, our findings suggest that the ability of Nutlin-3 to modulate dendritic cell functions and therefore lymphocyte proliferation might represent an additional important mechanism by which Nutlin-3 exerts its non cell-autonomous tumor-suppression function.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374325     DOI: 10.1016/j.humimm.2012.01.018

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  13 in total

1.  Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.

Authors:  Tania L Slatter; Michelle Wilson; Chingwen Tang; Hamish G Campbell; Vernon K Ward; Vivienne L Young; David Van Ly; Nicholas I Fleming; Antony W Braithwaite; Margaret A Baird
Journal:  Oncoimmunology       Date:  2015-12-17       Impact factor: 8.110

Review 2.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

Review 3.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

4.  New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.

Authors:  Gang Guo; Yan Cui
Journal:  J Immunother Cancer       Date:  2015-03-24       Impact factor: 13.751

5.  Autoantibody to MDM2: A Potential Serological Marker of Systemic Lupus Erythematosus.

Authors:  Yuan Liu; Liping Dai; Weihong Liu; Guixiu Shi; Jianying Zhang
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

Review 6.  Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.

Authors:  Yan Cui; Gang Guo
Journal:  Int J Mol Sci       Date:  2016-11-19       Impact factor: 5.923

7.  Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome.

Authors:  Yuan Liu; Xining Liao; Ying Wang; Shiju Chen; Yuechi Sun; Qingyan Lin; Guixiu Shi
Journal:  Oncotarget       Date:  2017-02-28

8.  Elucidation of the Mechanisms and Molecular Targets of Yiqi Shexue Formula for Treatment of Primary Immune Thrombocytopenia Based on Network Pharmacology.

Authors:  Yunyao Jiang; Nan Liu; Shirong Zhu; Xiaomei Hu; Dennis Chang; Jianxun Liu
Journal:  Front Pharmacol       Date:  2019-10-01       Impact factor: 5.810

9.  The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.

Authors:  Hongzhi Sun; Bo Zhang; Haijun Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.

Authors:  Dantong Sun; Dong Liu; Qiaoling Liu; Helei Hou
Journal:  Cancer Biol Ther       Date:  2020-11-05       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.